Search jobs 18-Jan-2021 ADDING MULTIMEDIA ENHERTU® Approved in the U.S. for the Treatment of Patients with Previously Treated HER2 Positive Advanced Gastric Cancer
First HER2 directed medicine approved for patients with gastric cancer in a decade
TOKYO & MUNICH & BASKING RIDGE, N.J. (BUSINESS WIRE) Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca’s
ENHERTU
® (fam-trastuzumab deruxtecan-nxki) has been approved in the U.S. for the treatment of adult patients with locally advanced or metastatic HER2 positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen.
In the U.S., gastric cancer is more frequently diagnosed in the advanced stage, with only approximately 5% of patients surviving five years.
Genus says profits surged higher in the first half, Centrica loses its CFO, Spirent says customers continue to invest in 5G during the pandemic, and PureTech announces Vor Biopharma has listed for an IPO in the US.
Hits: 1063
First HER2 directed medicine approved for patients with gastric cancer in a decade
TOKYO, Japan & MUNICH, Germany & BASKING RIDGE, NJ USA I January 15, 2021 I Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca’s
ENHERTU
® (fam-trastuzumab deruxtecan-nxki) has been approved in the U.S. for the treatment of adult patients with locally advanced or metastatic HER2 positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen.
In the U.S., gastric cancer is more frequently diagnosed in the advanced stage, with only approximately 5% of patients surviving five years.
1,2 Approximately one in five gastric cancers are HER2 positive.
ENHERTU Approved in the U S for the Treatment of Patients With Previously Treated HER2 Positive Advanced Gastric Cancer financialbuzz.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialbuzz.com Daily Mail and Mail on Sunday newspapers.